What does the evidence say about Chromium Fasting Glucose Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Chromium Fasting Glucose Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. [Babakr Abdullatif Taha (2026); evidence level 1] - 1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. [Babakr Abdullatif Taha (2026); evidence level 1] - 5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations. [Babakr Abdullatif Taha (2026); evidence level 1] - It includes central obesity, insulin resistance, hypertension, and dyslipidemia. [Babakr Abdullatif Taha (2026); evidence level 1] - Reduced insulin receptor sensitivity leads to a significant decline in insulin efficacy during glucose metabolism, further promoting hyperinsulinemia. [Ye Jiahui (2026); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.